Euprotec, Ltd. has entered an alliance with Cantab Anti-infectives to develop improved antibiotics to treat multidrug resistant Gram-negative bacterial infections.The program will focus on developing improved therapeutics based on polymyxin, a class of antibiotics with a unique and important target and are currently viewed as a last resort when treating severe infections due to multidrug resistant Gram negative bacteria.   Euprotec will provide microbiology services to help facilitate the identi...